Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
FRIDAY, Dec. 18, 2020 -- Immune checkpoint inhibitor (ICI) treatment is associated with increased cardiac events among patients with lung cancer and malignant melanoma, according to a study published online Dec. 9 in the European Heart...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Heart | Lung Cancer | Melanoma | Pharmaceuticals | Skin Cancer | Study